PF-Atlas › Clinical Trials › NCT02598193
Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis
Nintedanib · Phase 4
Registry ID
NCT02598193
Phase
Phase 4
Status
Completed
Drug / intervention
Nintedanib
Sponsor
Hoffmann-La Roche
Start
2016-01-14
About this trial
Nintedanib is evaluated in NCT02598193, a Phase 4 idiopathic pulmonary fibrosis study sponsored by Hoffmann-La Roche. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02598193 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.